LLS launches Team-in-Training app
The Leukemia & Lymphoma Society has just made it a lot easier and more convenient for people interested in staying in shape to do just that.
They have launched the Team4Cures app, which has been designed for the beginning athlete in mind and is prepped for whether they run, walk, swim, bike or hike. It will help them set and track fitness goals, which they can also share with their friends on Facebook, and Twitter.
The app is especially geared towards the hundreds of thousands of people who are or who have taken part in the LLS' spectacularly successful Team-in-Training (TNT) program.
Said Nancy L. Klein, chief marketing and revenue officer for the LLS, "[Our] Team In Training has been applauded for its success in inspiring hundreds of thousands of individuals to improve their health and fitness, and achieve their goals of completing a marathon, half marathon, triathlon, century ride or hike adventure.
"This new app will give more people a fun and simple way to meet their fitness goals and let them learn more about the Team In Training program."
Source: LLS
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
